| Urbanise.Com Limited (UBN) ORDINARY FULLY PAID |
Information Technology |
$55 |
Appendix 4E - 30 June 2026
|
26 Aug 2026 9:04AM |
$0.670 |
$0.690 |
risen by
2.99%
|
|
UBN - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities increased by 14.3% from the previous year.
- Loss from ordinary activities after tax decreased by 76.0%.
- Basic loss per share improved from (5.47) cents to (1.10) cents.
- Net tangible assets per ordinary share increased from 8.73 cents to 9.85 cents.
- Urbanise.com Limited did not gain control over any new entities.
- There are no associates or joint ventures within the Urbanise Group.
- No dividends were paid or declared during the period.
- The financial statements have been audited and an unqualified opinion was issued.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aeeris Ltd (AER) ORDINARY FULLY PAID |
Communication Services |
$5 |
Appendix 4E and FY26 Annual Report
|
26 Aug 2026 9:04AM |
$0.060 |
$0.060 |
fallen by
0%
|
|
AER - Price-sensitive ASX Announcement
Full Release
Key Points
- Total trading income of $3.82 million, a slight decrease from $3.84 million in FY25.
- Gross profit increased by 16% to $3.40 million, with gross margin expanding to 89.0%.
- Operating expenses rose by 4.7% to $4.27 million.
- Received a research and development tax incentive of $0.51 million.
- Statutory net loss reduced by 44.4% to $349,001.
- Net cash used in operating activities improved to $0.06 million.
- Net assets reduced to $0.80 million, maintaining a conservative capital structure.
- Launch of the New Dawn Strategy to reposition as a customer-led impact intelligence business.
- Aeeris maintained ISO 27001:2022 certification, enhancing platform resilience.
- Focus on strengthening operations and profitability under the New Dawn Strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vitura Health Limited (VIT) ORDINARY FULLY PAID |
Health Care |
$17 |
2026 Financial Report
|
26 Aug 2026 9:04AM |
$0.031 |
$0.025 |
fallen by
19.35%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$69 |
Retirement of Non-Executive Director Kevin Eley
|
26 Aug 2026 9:04AM |
$0.725 |
$0.710 |
fallen by
2.07%
|
|
| Mastermyne Group Limited (MYE) ORDINARY FULLY PAID |
Materials |
$195 |
Preliminary Final Report
|
26 Aug 2026 9:03AM |
$0.600 |
$0.633 |
risen by
5.42%
|
|
MYE - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations increased by 13% to $237,697,000.
- Underlying profit before tax grew by 148% to $15,710,000.
- The statutory net profit after tax was $2,003,000, a 17% increase from the previous year.
- Basic earnings per share remained consistent at 0.7 cents.
- No dividends were declared or paid for the year ending 30 June 2026.
- Net tangible assets per ordinary security increased to $0.21.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$1,877 |
Update - Notification of buy-back - MGH
|
26 Aug 2026 9:03AM |
$5.790 |
$5.195 |
fallen by
10.28%
|
|
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$25,748 |
Notification of cessation of securities - BXB
|
26 Aug 2026 9:03AM |
$19.440 |
$19.315 |
fallen by
0.64%
|
|
| QuickFee Limited (QFE) ORDINARY FULLY PAID |
Financials |
$31 |
Change of Directors Interest Notice - Bruce Coombes
|
26 Aug 2026 9:03AM |
$0.081 |
$0.080 |
fallen by
1.23%
|
|
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$4,750 |
Corporate Governance Statement 2026
|
26 Aug 2026 9:02AM |
$11.100 |
$9.740 |
fallen by
12.25%
|
|
| COG Financial Services Limited (COG) ORDINARY FULLY PAID |
Financials |
$337 |
Dividend/Distribution - COG
|
26 Aug 2026 9:02AM |
$1.460 |
$1.580 |
risen by
8.22%
|
|
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$4,750 |
Annual Report to shareholders
|
26 Aug 2026 9:02AM |
$11.100 |
$9.740 |
fallen by
12.25%
|
|
| COG Financial Services Limited (COG) ORDINARY FULLY PAID |
Financials |
$337 |
Appendix 4G and Corporate Governance Statement
|
26 Aug 2026 9:02AM |
$1.460 |
$1.580 |
risen by
8.22%
|
|
| COG Financial Services Limited (COG) ORDINARY FULLY PAID |
Financials |
$337 |
Appendix 4E, Audited Financial Statements and Annual Report
|
26 Aug 2026 9:01AM |
$1.460 |
$1.580 |
risen by
8.22%
|
|
| Commonwealth Bank of Australia (CBA) ORDINARY FULLY PAID |
Financials |
$268,909 |
Agreement reached to settle class action
|
26 Aug 2026 9:01AM |
$157.010 |
$160.690 |
risen by
2.34%
|
|
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$4,750 |
ASX presentation - Full year results 2026
|
26 Aug 2026 9:00AM |
$11.100 |
$9.740 |
fallen by
12.25%
|
|
WOR - Price-sensitive ASX Announcement
Full Release
Key Points
- Aggregated revenue slightly down to $12,023 million from $12,050 million.
- Underlying EBITA decreased by 10.8% to $734 million.
- Strong cash conversion ratio at 93.6%.
- Final dividend maintained at 25 cents per share.
- Focus on energy transition and AI-enabled project delivery.
- Diversification across sectors and regions for resilience.
- Impact from Middle East disruptions and foreign exchange translation.
- Continued investment in future growth markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Far Limited (FAR) ORDINARY FULLY PAID |
Energy |
$26 |
Half Year Report and Accounts
|
26 Aug 2026 9:00AM |
$0.300 |
$0.285 |
fallen by
5%
|
|
FAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit of US$1,442,226 for the half-year ended 30 June 2026.
- Rights to a Consideration Receivable from Woodside Energy up to US$55 million.
- Capital return of approximately A$32.3 million to shareholders.
- No dividends paid, recommended, or declared during this period.
- Significant executive changes including the appointment of a new CFO and Company Secretary.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$4,750 |
ASX release - Full year results 2026
|
26 Aug 2026 8:59AM |
$11.100 |
$9.740 |
fallen by
12.25%
|
|
WOR - Price-sensitive ASX Announcement
Full Release
Key Points
- Full-year results for FY26 with statutory net profit of $306 million.
- Aggregated revenue stable at $12,023 million.
- Underlying EBITA of $734 million, down 10.8% on previous corresponding period.
- Middle East conflict and currency translation impacted earnings.
- Cost-out initiatives of $132 million exceeded initial target.
- Strong bookings of $15.5 billion, up 23% from FY25.
- Backlog of $13.8 billion, up 9% from 30 June 2025.
- Unfranked final dividend of 25 cents per share declared.
- Completed $500 million share buyback, with $300 million more planned.
- Anticipates mid to high single-digit growth in revenue and EBITA for FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID |
Health Care |
$41 |
RAD Doses First Patient in Second Cohort of BetaBart (RV-01)
|
26 Aug 2026 8:59AM |
$0.011 |
$0.010 |
fallen by
9.52%
|
|
RAD - Price-sensitive ASX Announcement
Full Release
Key Points
- Radiopharm Theranostics doses the first patient in the second cohort of BetaBart (RV-01) clinical trial.
- The trial is a Phase 1/2a study focused on B7-H3 expressing solid tumors.
- RV-01 is a 177Lutetium-conjugated therapeutic targeting B7-H3, a molecule overexpressed in various tumor types.
- The clinical trial aims to evaluate the safety, biodistribution, and anti-tumor activity of RV-01.
- The trial is conducted at clinical centers across the U.S.
- Phase 1/2a study will determine the recommended dose for future studies.
- Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on oncology radiopharmaceuticals.
- The study aims to enroll 61 participants with a history of various confirmed cancers.
- The 70 mCi dose level was recommended by the Safety and Monitoring Committee.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Green & Gold Minerals Limited (GG1) ORDINARY FULLY PAID |
Materials |
$9 |
Outstanding Copper-Silver-Tin at Elizabeth Bluffs
|
26 Aug 2026 8:59AM |
$0.145 |
$0.140 |
fallen by
3.45%
|
|
GG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- High-grade copper-silver-tin potential identified at Elizabeth Bluffs.
- Historic and recent sampling confirm copper, silver, and tin presence.
- Past assays show high grades of copper and gold.
- GG1's rock chip sampling verifies significant mineral concentrations.
- Planned 3000m drilling campaign at Mt Wandoo to start in September 2026.
- Elizabeth Bluffs contains a 4km long mineralised chert zone.
- Historic mining focused on tin with significant copper-silver results.
- Underground sampling reveals significant copper and tin widths.
- Exploration model involves intrusion-related metal systems.
- Planned further geological mapping and drilling to define targets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$4,750 |
Dividend/Distribution - WOR
|
26 Aug 2026 8:59AM |
$11.100 |
$9.740 |
fallen by
12.25%
|
|
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$4,750 |
Appendix 4E 2026
|
26 Aug 2026 8:59AM |
$11.100 |
$9.740 |
fallen by
12.25%
|
|
WOR - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory revenue and other income decreased by 5% to $10,714 million.
- EBITA decreased by 25% to $614 million.
- NPATA decreased by 36% to $306 million.
- Total dividend of 50.0 cents per share declared.
- Costs related to transformation and restructuring excluded from underlying results.
- Appendix 4E derived from audited annual report by PWC.
- Emphasis on understanding underlying profit by excluding significant items and amortization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wisetech Global Limited (WTC) ORDINARY FULLY PAID |
Information Technology |
$12,453 |
WiseTech Global FY26 results investor presentation
|
26 Aug 2026 8:58AM |
$45.470 |
$37.030 |
fallen by
18.56%
|
|
WTC - Price-sensitive ASX Announcement
Full Release
Key Points
- FY26 revenue increased by 79% to AUD 1,395.9 million.
- Underlying EBITDA rose by 56% to AUD 644.5 million.
- AI-driven transformation contributed to AUD 34 million in annualized run-rate savings.
- 95% of total revenue was from recurring sources.
- CargoWise revenue grew by 11% to AUD 756.9 million.
- Net leverage ratio was at 2.7x with plans for further reduction.
- Strategic focus on AI efficiency and productivity gains.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana International Equities Limited (PIA) ORDINARY FULLY PAID |
Financials |
$276 |
NTA at 21.08.26 Pre-tax 125.10 Post-tax 121.99
|
26 Aug 2026 8:58AM |
$1.105 |
$1.070 |
fallen by
3.17%
|
|
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$25 |
BCAL Takes Interest in Genetic Signatures to 18.46%
|
26 Aug 2026 8:57AM |
$0.052 |
$0.069 |
risen by
32.69%
|
|
BDX - Price-sensitive ASX Announcement
Full Release
Key Points
- BCAL increased its stake in Genetic Signatures Ltd to 18.46%.
- Acquisition involved 18.75 million shares for $1.5 million.
- Investment is to enhance BCAL's diagnostic platform and growth.
- BCAL focuses on early cancer detection and is based in Sydney.
- BCAL is listed on the Australian Securities Exchange as BDX.
- Genetic Signatures specializes in molecular diagnostics with 3base® technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wisetech Global Limited (WTC) ORDINARY FULLY PAID |
Information Technology |
$12,453 |
WTC record revenue, up 79%, exceeds guidance EBITDA, up 54%
|
26 Aug 2026 8:57AM |
$45.470 |
$37.030 |
fallen by
18.56%
|
|
WTC - Price-sensitive ASX Announcement
Full Release
Key Points
- WiseTech Global's revenue increased by 79% in FY26, reaching $1,395.9 million, driven by the acquisition of e2open.
- The company's EBITDA was $558.4 million, up 46% from FY25, with an EBITDA margin of 40%.
- Underlying EBITDA was $644.5 million, up 56% with a margin of 46%.
- WiseTech achieved $115 million in annualized run-rate cost savings through various efficiency programs.
- Over 95% of CargoWise customers have transitioned to the new CargoWise Value Packs model.
- The company achieved a record Underlying Rule of 40 of 114%, significantly up from 52% in FY25.
- WiseTech's operating cash flow was $564 million, up 29%, with free cash flow of $410.7 million, up 43%.
- The company continues to integrate and standardize e2open, achieving better-than-expected EBITDA margin improvements.
- WiseTech's strategic initiatives include AI adoption and expanding product offerings with acquisitions like FRDM.ai.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
